Overview Risks Symptoms Diagnosis Treatment Management What is non-small cell lung cancer?Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.What are the subtypes of NSCLC?Squamous cell carcinoma is found in cells that line the airways of the lungs. It is usually ...
TREATMENTLung CancerNon-Small Cell Lung CancerDIAGNOSISLung cancer is becoming the most common cancer globally. In China, Lung cancer has become prevalent among preceding compared to present smokers. There are many treatments for lung cancer globally like Chemotherapy, Radiotherapy, Surgery, and Targeted...
Based on what your doctor finds, they'll assign a stage, describing where thecanceris. That will help your medical team figure out the best treatment for you. You’ll want to know what each stage means: Occult stage: "Occult" means "hidden." Cancer cells are in lung fluid or sputum, ...
The backbone of treatment for small cell lung cancer (SCLC) is chemotherapy. Standard treatments remain platinum- or anthracycline-based and have changed little over the past ten years. The most recent first-line contender has been amrubicin, a third generation synthetic anthracycline agent which doe...
Next-generation sequencing and other high-throughput analyses have begun to show the many different molecular and genetic subsets of non-small-cell lung cancer (NSCLC) and have drastically altered the clinical evaluation and treatment of patients during the past decade. The pathological features and ...
KEYTRUDA is a prescription medicine used to treat a kind of lung cancer called non–small cell lung cancer (NSCLC). KEYTRUDA may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread (advanced NSCLC)andis a type called “non...
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational r
非小细胞肺癌(non-small cell lung cancer,NSCLC)占所有新诊断肺癌病例的85%。约20%的NSCLC在初诊时为Ⅰ期和Ⅱ期,30%为Ⅲ期[1]。近年来,随着低剂量计算机断层扫描(CT)筛查胸部疾病的日益普及,早期NSCLC的诊断率不断提高。Ⅰ~ⅢA期NSCLC的主要治疗方法是根治性手术,并酌情结合新辅助或辅助治疗[2]。在NSCLC完全...
The efficacy of checkpoint inhibitor (CPI) immunotherapy in patients with non–small cell lung cancer (NSCLC) is limited by a lack of strongly predictive response markers, subjecting patients to potential underutilization of alternative effective treatments, increased risk for futile care, and unnecessar...
Summary: Between January 1, 1991 until December 31, 1996, 286 patients with non-small cell lung cancer were diagnosed and treated in the Department of Tuberculosis and Respiratory Diseases and Palliative Care Unit in Babice nad Svitavou, Czech Republic. There were 251 (87.8 %) males and 35 (...